SIMCERE PHARMA (02096.HK): Sublingual Stroke Drug Added to 2026 National Reimbursement List
NewTimeSpace News: On 16 November 2026, Simcere Pharmaceutical Group Limited (stock code: 2096) published a voluntary announcement that on 14 November 2026 its edaravone/dexborneol sublingual tablets were formally added to the 2026 edition of the National Reimbursement Drug List issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, effective 1 January 2027. The related injection completed its third reimbursement renewal.
The sublingual tablets are a brain cell protectant combining edaravone and dexborneol, with antioxidant, anti-inflammatory and synergistic effects that significantly reduce brain cell damage caused by acute ischaemic stroke. The sublingual form disintegrates rapidly on contact with saliva and is absorbed quickly through the sublingual venous plexus, adding flexibility to stroke treatment and forming a sequential regimen with the injection so that patients can complete a full course in and after hospital. With both forms listed, the 14-day full treatment course for acute ischaemic stroke is expected to be covered.
The sublingual tablets were approved in China in December 2024 to improve neurological symptoms, activities of daily living and functional impairment caused by acute ischaemic stroke. In August 2024 the product received the US FDA's breakthrough therapy designation, the first innovative drug in the global stroke field and in China's neuroscience field to obtain it.
- Fullgoal Hang Seng HK High Dividend ETF (03031.HK) Down 1.54% as Hong Kong Stocks Slide
- PINESTONE (00804.HK): Appoints Wu Yuanzheng as AI Business GM
- ALPHA PRO HLDGS (00948.HK): Clarifies 56.62M Excess Rights Shares
- EDDING GENOR (06998.HK): GB268 Wins NMPA Nod for NSCLC, BTC Trials
- HENLIUS (02696.HK): NMPA Clears HLX105 Phase 1 Solid Tumour IND